71 results
To evaluate the safety and toxicity of ACT and low-dose IFN-alpha plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that do not result in treatment termination are considered acceptable for…
Objectives in adult patientsPrimary Objective:To demonstrate the efficacy of Holoclar® at one year after the first treatment in patients suffering from moderate (vascularization in two-three corneal quadrants with central corneal involvement) to…
Primary objectives- To evaluate the feasibility of leukapheresis and the production of human clinical-grade proinsulin-peptideC19-A3-pulsed TolDCs (PIpepTolDCs) in type 1 Diabetes Mellitus patients.- To evaluate the safety of clinical use of…
The objectives and relevant endpoints of the study are as follows:Primary: To assess the safety and tolerability of ATL001 as amonotherapy and in combination with pembrolizumabSecondary: To evaluate the clinical efficacy of ATL001treatment as a…
Primary:• To evaluate AD-specific, neuroinflammatory, neurotrophic and neurodegenerative biomarkers and safety of 3 intrathecal (IT) administrations of NurOwn® (MSC-NTF cells) given at two monthly intervals to participants with prodromal to mild…
The phase I/IIa trial will consist of an intra-arterial injection (via catheter in femoral artery) of autologous MABs in the left lower leg of 5 m.3243A>G patients. The primary objective is assessing safety of administration of autologous…
Primary ObjectivesPart 1 (Monotherapy Dose Escalation Phase):* To determine the recommended Phase 2 dose (RP2D) of SQZ AAC HPV monotherapy. * To characterize the safety and tolerability of SQZ AAC HPV administered as monotherapy. Part 2 (Combination…
The main objective of this study is to test the hypothesis that SVF alleviates pain and increases maximal interincisal mouth opening in patients with TMJ osteoarthritis.
Primary Objective:To evaluate the efficacy of LN-145 measured by objective response rate (ORR) usingResponse Evaluation Criteria in Solid Tumors (RECIST) v1.1 assessed by theIndependent Review Committee (IRC) for Cohorts 1 and 2 and by the…
To investigate safety and tolerability as well as the induced immune response upon MesoPher/mitazalimab combination therapy in metastasized pancreatic disease after (modified) FOLFIRINOX.
To assess whether (neo)-adjuvant DCT in combination with eP/D is feasible in early stage epithelioid MPM patients after first-line chemotherapy.